NGM BIOPHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of 0IK for the last quarter is 149.49 k EUR, and it's 72.85% lower compared to the previous quarter. The net income of Q4 23 is -25.07 M EUR.